Analysts expect Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings of ($0.08) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Progenics Pharmaceuticals’ earnings, with estimates ranging from ($0.13) to ($0.02). Progenics Pharmaceuticals posted earnings per share of ($0.21) during the same quarter last year, which indicates a positive year over year growth rate of 61.9%. The company is expected to announce its next earnings report on Thursday, March 14th.
On average, analysts expect that Progenics Pharmaceuticals will report full year earnings of ($0.77) per share for the current year, with EPS estimates ranging from ($0.82) to ($0.71). For the next financial year, analysts expect that the firm will report earnings of ($0.32) per share, with EPS estimates ranging from ($0.39) to ($0.25). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Progenics Pharmaceuticals.
Progenics Pharmaceuticals (NASDAQ:PGNX) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.09. Progenics Pharmaceuticals had a negative net margin of 341.78% and a negative return on equity of 66.86%. The company had revenue of $5.32 million for the quarter, compared to analyst estimates of $4.14 million.
A number of research firms recently weighed in on PGNX. BidaskClub raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 20th. Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 10th. Credit Suisse Group began coverage on shares of Progenics Pharmaceuticals in a report on Friday, December 7th. They set an “outperform” rating and a $6.50 price target for the company. ValuEngine raised shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 8th. Finally, Needham & Company LLC lowered shares of Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating and lowered their price target for the company from $16.00 to $12.00 in a report on Thursday, September 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $11.63.
Shares of Progenics Pharmaceuticals stock traded down $0.08 during trading hours on Friday, hitting $4.72. The company’s stock had a trading volume of 274,057 shares, compared to its average volume of 1,366,563. Progenics Pharmaceuticals has a 1-year low of $3.62 and a 1-year high of $9.42. The firm has a market capitalization of $390.59 million, a P/E ratio of -5.24 and a beta of 2.57. The company has a quick ratio of 9.51, a current ratio of 9.51 and a debt-to-equity ratio of 0.33.
Several institutional investors have recently bought and sold shares of PGNX. BlackRock Inc. grew its stake in shares of Progenics Pharmaceuticals by 16.7% in the 3rd quarter. BlackRock Inc. now owns 13,293,243 shares of the biotechnology company’s stock worth $83,349,000 after purchasing an additional 1,902,006 shares during the last quarter. Vanguard Group Inc increased its position in shares of Progenics Pharmaceuticals by 16.8% in the third quarter. Vanguard Group Inc now owns 5,046,431 shares of the biotechnology company’s stock worth $31,641,000 after acquiring an additional 727,575 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Progenics Pharmaceuticals by 16.8% in the third quarter. Vanguard Group Inc. now owns 5,046,431 shares of the biotechnology company’s stock worth $31,641,000 after acquiring an additional 727,575 shares in the last quarter. Fosun International Ltd purchased a new position in shares of Progenics Pharmaceuticals in the third quarter worth approximately $2,463,000. Finally, Royce & Associates LP increased its position in shares of Progenics Pharmaceuticals by 23.5% in the third quarter. Royce & Associates LP now owns 1,453,456 shares of the biotechnology company’s stock worth $9,113,000 after acquiring an additional 276,200 shares in the last quarter. Institutional investors own 92.07% of the company’s stock.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.
Featured Story: What strategies should day traders use to execute a trade?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.